Managing Stable Ischemic Heart Disease: Translating Evidence into Practice
2.00 AMA PRA Category 1 Credits
- Demonstrate accurate diagnosis and assessment of risk in patients with stable angina.
- Describe mechanisms of action, unique properties, and clinical data associated with traditional and newer antianginal therapies.
- Identify optimal medical therapy for stable ischemic heart disease patients and recognize its importance for preventing MI and death.
- Discuss clinical trial evidence comparing prompt revascularization with optimal medical therapy, with optimal medical therapy alone, and elaborate appropriate use of revascularization in patients with stable ischemic heart disease.
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
||AMA PRA Category 1 Credits
||pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||pmiCME designates this enduring material activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
William E. Boden, MD, (Read Bio), Professor of Medicine, Albany Medical College, Chief of Medicine, Albany VA Medical Center, Albany, New York
Benjamin M. Scirica , MD, MPH, (Read Bio), Assistant Professor, Harvard Medical School, Director TIMI ECG Core Lab, Director TIMI ECG Core Lab, Brigham and Women’s Hospital, Boston, Massachusetts
Carolyn Skowronski, PharmD, Medical Director, pmiCME
Financial Disclosure Statement(s)
Dr William Boden indicates he has nothing to disclose.
Dr Benjamin Scirica indicates he has received research grant support from AstraZeneca, Daiichi-Sankyo, Merck, Bristol-Myers Squibb, Johnson and Johnson, Bayer Healthcare, Novartis, and Gilead Sciences Medical Affairs. He has received honoraria from Gilead, Arena Pharmaceuticals, and Lexicon. Dr. Scirica intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
John F. Kocsis, PhD, Voxmedia, has nothing to disclose.
Dr Skowronski holds stock in Merck & Co.
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached post-activity assessment and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.